ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 861

ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?

Valeria Scaglioni1, Marina Scolnik1, Luis J. Catoggio1, Carlos Federico Varela2, Gustavo Greloni2, Silvia Christiansen3 and Enrique R. Soriano4, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Internal Medicine, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA, glomerulonephritis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN) is considered a “pauci-immune” disease, characterized by absent or mild glomerular tuft staining for immunoglobulin and/or complement. However, it is not unusual for renal biopsies in such cases to exhibit some immune complex (IC) deposition within glomeruli on immunofluorescence (IF) and/or electron microscopic study. Their potential pathologic and clinical significance is not clear, although a possible synergistic effect between immune complexes and ANCA in producing more severe glomerulonephritis is suggested by some authors. The aim of this study was to evaluate the prevalence and clinical significance of immune deposits in ANCA-associated pauci-immune GN.

Methods:

We included retrospectively all patients with biopsy-proven ANCA GN: granulomatosis with polyangiitis (GPA), granulomatosis with polyangiitis and eosinophilia (GPAE), microscopic polyangiitis (PAM) and renal limited vasculitis (RLV) between January 2002 and May 2013. Patients were divided into 2 groups: Group A: biopsy without IC deposits (less than 2+ intensity of immunostaining) and Group B: biopsy with IC deposits (more than 2+ intensity of immunostaining). IF included Ig (IgG, IgA and IgM) and complement components (C3 and C1q). Serum creatinine, estimated glomerular filtration rate (eGFR) at time of the biopsy, amount of proteinuria and hematuria, requirement of dialysis and extra renal involvement were recorded. 

Results:

Fifty-three patients (75.4% females) were included. The mean age at the time of the biopsy was 66.3 (SD: 14.3). Typical pauci-immune GN was found in 39 patients (73.5%, group A). In 14 patients (26.4%, group B) histopathological examination revealed substantial deposition of Ig or complement in the mesangium and/or along the glomerular capillary wall. IC deposition was more frequent in GPA and GPAE compared with PAM and RLV. C3 deposition on the capillary wall was the most frequent finding (64.2%), followed by C3 + IgG (21.4%) and IgG alone (14.2%). No patient presented positive staining for C1q. IgM and IgA were found only in two patients but along with C3. Compared with patients in group A, those in group B demonstrated significantly more 24 h proteinuria (mean 0.8 (SD: 7.6) vs 1.6 (SD: 10.7), p= 0.0036). No differences between groups were found related to age, gender, renal function, extra renal organ involvement at the time of biopsy, and in response to induction therapy (table 1).

Conclusion:

Our results confirm that in ANCA GN a substantial percentage of patients have evidence of Ig or C3 deposition in renal biopsies (26.4%). In this subgroup, IC deposition was associated with a significantly greater degree of proteinuria. Further clinical and basic research is needed to elucidate the significance of IC deposition in ANCA GN.

TABLE 1. DIFFERENCES BETWEEN THE GROUPS 

 

GROUP A, N=39

(less than 2+ intensity of immunostaining)

GROUP B, N=14

(more than 2+ intensity of immunostaining)

p

Mean age (SD)

67.6 (15.4)

62.6 (10.1)

.26

Females, n (%)

29 (72.5)

10 (76.2)

.75

Diagnosis, n (%)

–       GPA

–       GPAE

–       PAM

–       RLV

9 (60)

3 (60)

9 (90)

18 (78)

6 (40)

2 (40)

1 (10)

5 (22)

 

Mean Baseline Creatinine mg/dl, (SD)

3 (28.2)

3.4 (23.5)

.69

Extra-renal involvement; n, (%)

19 (48.7)

7 (50)

.93

Mean Proteinuria g/24 h, (SD)

0.8 (7.6)

1.6 (10.7)

.0036

Remission after induction treatment; n (%)

26 (74.2)

11 (68.7)

.68


Disclosure: V. Scaglioni, None; M. Scolnik, None; L. J. Catoggio, None; C. F. Varela, None; G. Greloni, None; S. Christiansen, None; E. R. Soriano, Abbvie; Janssen; UCB; Roche; Bristol Myers Squibb, 2,Abbvie; UCB; Janssen; Roche; Bristol Myers Squibb; Pfizer; Novartis, 8.

To cite this abstract in AMA style:

Scaglioni V, Scolnik M, Catoggio LJ, Varela CF, Greloni G, Christiansen S, Soriano ER. ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anca-associated-pauci-immune-glomerulonephritis-always-pauci-immune/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anca-associated-pauci-immune-glomerulonephritis-always-pauci-immune/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology